CIBC Private Wealth Group’s Myriad Genetics MYGN Stock Holding History

CIBC Private Wealth Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$135	Buy	+22	New	+$160	﹤0.01%	3277
2024 Q4	–	Sell	-400	Closed	-$11K	–	3115
2024 Q3	$11K	Hold	400	–	–	﹤0.01%	2377
2024 Q2	$10.1K	Hold	400	–	–	﹤0.01%	2291
2024 Q1	$8.58K	Buy	+400	New	+$8.6K	﹤0.01%	2338
2018 Q4	–	Sell	-12,395	Closed	-$570K	–	919
2018 Q3	$570K	Buy	12,395 +11,895	+2,379%	+$529K	﹤0.01%	749
2018 Q2	$19K	Hold	500	–	–	﹤0.01%	1418
2018 Q1	$15K	Sell	500 -5	-1%	-$169	﹤0.01%	1446
2017 Q4	$17K	Buy	+505	New	+$17K	﹤0.01%	1435
2015 Q4	–	Sell	-10,935	Closed	-$410K	–	593
2015 Q3	$410K	Sell	10,935 -1,460	-12%	-$51.8K	﹤0.01%	549
2015 Q2	$421K	Sell	12,395 -1,000	-7%	-$34K	﹤0.01%	567
2015 Q1	$474K	Buy	+13,395	New	+$479K	﹤0.01%	555

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CIBC Private Wealth Group's MYGN Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Myriad Genetics (MYGN) in Q4 2025: 22 shares worth $135. The stake represents ﹤0.01% of the portfolio and ranks #3277 among its holdings. This is a return to the name: CIBC Private Wealth Group previously reported a position in MYGN as recently as Q3 2024.

CIBC Private Wealth Group first reported a position in MYGN in Q1 2015 and has held it in 11 quarters since. The position peaked at $570K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

CIBC Private Wealth Group held 22 shares of Myriad Genetics worth $135 as of Q4 2025.
Myriad Genetics was a new CIBC Private Wealth Group position in Q4 2025.
Myriad Genetics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3277 holding.
CIBC Private Wealth Group first reported a position in Myriad Genetics in Q1 2015 and has held it in 11 quarters since.
CIBC Private Wealth Group's Myriad Genetics position peaked at $570K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.